Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MicroPine
- Development stage
- Discontinued
- Lead developer
- Hyperion DeFi
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
MicroPine is an investigational ophthalmic spray formulation of atropine, delivered via Eyenovia’s proprietary Optejet microdose dispenser. It is being developed as a treatment to slow the progression of pediatric progressive myopia (nearsightedness) in children. The drug-device combination aims to provide precise, low-dose delivery of atropine directly to the eye as a gentle mist, potentially improving compliance and reducing systemic exposure compared to traditional eye drops. Atropine acts as a non-selective muscarinic acetylcholine receptor antagonist in the eye, which has been shown in clinical studies to slow axial elongation and myopic progression by up to 60%. MicroPine is currently in late phase III clinical trials for this indication and has not yet received FDA approval[1][2][3][6][7].
- Brand names
- MicroPine
- Other names
- MicroPine
02
Targets
M1 (Muscarinic acetylcholine receptor M1)CHRM2 (M2)CHRM4 (M4)
Beyond the preview
Go deeper on MicroPine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MicroPine.